As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.

Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.

At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how onshoring, geopolitical risk and a shifting product mix are driving supply chain automation.

At LogiPharma USA 2026, quality leaders explained why connected data, risk-based prioritization, and human accountability must come before AI in supply chain compliance.

At LogiPharma USA 2026, leaders from J&J, Sun Pharma, Accord Healthcare, and Freehand discussed visibility, redundancy tradeoffs, and AI's role in resilient pharma supply chains.

LogiPharma's Charleen Ring and McKesson's Chris Van Norman preview the 2026 agenda, sessions to prioritize and a day two fireside chat.

In this Q&A, Doceree CEO Harshit Jain, MD, explains why AI should inform prescribing decisions, not drive them, and how sales reps own relationships while AI extends reach.

Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.